𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Immunosuppressive therapy and virus-cores in HBAg-positive chronic hepatitis

✍ Scribed by Kendrey, G. ;Szalka, A. ;László, B. ;Binder, L. ;Hollós, I.

Publisher
Springer-Verlag
Year
1975
Tongue
English
Weight
359 KB
Volume
53
Category
Article
ISSN
1432-1440

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Strategies to prevent hepatitis B virus
Strategies to prevent hepatitis B virus reactivation in patients receiving immunosuppressive therapy
✍ Chiun Hsu; Shu-Chen Wei; Ann-Lii Cheng; Pei-Jer Chen 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB

prednisone at 50 mg/day and azathioprine at 50 mg/day was initiated. Of note, liver function tests (LFTs) were normal at this time. Two weeks later, the patient was well, prednisone was completely tapered, and azathioprine was increased to 100 mg/day. Three months later, the patient presented to the

Liver disease activity and hepatitis B v
Liver disease activity and hepatitis B virus replication in chronic delta antigen-positive hepatitis B virus carriers
✍ Stephanos J. Hadziyannis; Morris Sherman; Harvey M. Lieberman; David A. Shafritz 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 480 KB 👁 2 views

Delta antigen is currently thought to reflect superinfection of the liver with a defective RNA virus (delta agent), requiring helper function from hepatitis B virus for its replication. To assess the influence of delta agent on hepatitis B virus replication in patients persistently infected with bot

Foscarnet therapy in chronic hepatitis B
Foscarnet therapy in chronic hepatitis B virus e antigen carriers
✍ V. G. Bain; H. M. Daniels; A. Chanas; G. J. M. Alexander; Dr. Roger Williams 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 343 KB 👁 2 views

Foscarnet (trisodium phosphonoformate) is a novel antiviral agent that inhibits viral-specific DNA polymerase. In the present study, eight males with chronic HBV carriage (HBeAg and HBV-DNA seropositivity >I2 months) showing chronic persistent hepatitis (CPH) or chronic active hepatitis (CAH) on liv

Effect of Immunosuppressive Therapy on H
Effect of Immunosuppressive Therapy on HBsAg-Positive Chronic Active Hepatitis in Relation to Presence or Absence of HBeAg and Anti-HBe
✍ Evangelista Sagnelli; Felice Piccinino; Giuseppe Manzillo; Francesca M. Felaco; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 556 KB

Two hundred and four patients with biopsy-proven HBsAg-positive chronic active hepatitis were treated for at least 2 years with azathioprine, prednisolone or a combination of both, or were untreated. Prevalences of HBeAg, anti-HBe, and anti-HBc were 26, 58, and loo%, respectively. Criteria for impro